SGLT2 inhibitors × glycemic control

TrialDiabetes & metabolism journal2023

Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.

Kyung Ah Han et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 200 people · 2023

Range includes no effect

No clear effect on glycemic control

−0.04percentage points−0.21 to +0.12

As reported

difference −0.04 %, 95% CI −0.21 to 0.12

One number in the abstract

the abstract, start to end

-0.75% with dapagliflozin (difference, -0.04%; 95% confidence interval,

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.04−0.21 to 0.12
SGLT2 inhibitorsGlycemic control
1 / 3

10 papers cite it

2023
2024
2025
2026
this papertrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 36756676